- Integration of CiNii Books functions for fiscal year 2025 has completed
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on November 26, 2025】Regarding the recording of “Research Data” and “Evidence Data”
- Start the collection of all publicly IRDB content
- Incorporate Research Data from KAKEN
Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes
-
- Tosaki Takahiro
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Kamiya Hideki
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
-
- Yamamoto Yuka
- Department of Diabetes and Endocrinology, Meieki East Clinic, Japan
-
- Himeno Tatsuhito
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
-
- Kato Yoshiro
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
-
- Kondo Masaki
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
-
- Yamada Yuichiro
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
-
- Inagaki Akemi
- Department of Diabetes and Endocrinology, Japanese Red Cross Nagoya Daini Hospital, Japan
-
- Tsubonaka Kaori
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Oshiro Chie
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Katayama Takami
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Hayasaki Tomoyo
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Nakaya Yuki
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Fujiyoshi Haruna
- TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology, Japan
-
- Nakamura Jiro
- Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan
Bibliographic Information
- Published
- 2017
- Resource Type
- journal article
- DOI
-
- 10.2169/internalmedicine.8184-16
- Publisher
- The Japanese Society of Internal Medicine
Search this article
Description
<p>Objective We investigated the efficacy, safety, and patient satisfaction of once-weekly DPP-4 inhibitors (DPP-4Is). </p><p>Methods Either of two once-weekly DPP-4Is, trelagliptin or omarigliptin, was administered alone or in combination with other antidiabetic drugs in 80 outpatients with type 2 diabetes mellitus for 3 months. The HbA1c, glycoalbumin (GA), body weight, and the Diabetes Treatment Satisfaction Questionnaire (DTSQ) scores were evaluated. </p><p>Results Patients switching from other daily DPP-4Is (n=29) showed no significant changes in the HbA1c or GA levels. However, the HbA1c and GA levels of patients who had been naïve to DPP-4Is (n=37) significantly improved from 9.31±2.53% to 7.02±1.20% (p<0.001) and 26.7±11.8% to 17.3±5.7% (p<0.001), respectively. Several non-serious adverse events were reported, including nausea (n=1), abdominal distension (n=1), and constipation (n=1). In the DTSQs, the total score for six questions on the primary factors representing patient treatment satisfaction was not markedly changed in patients switching from daily to weekly DPP-4Is but was significantly improved from 21.0 to 28.0 (p<0.001) in patients naïve to DPP-4Is. </p><p>Conclusion These findings suggest that the use of a once-weekly DPP-4I is effective and well-tolerated in diabetes treatment and improves treatment satisfaction. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 56 (19), 2563-2569, 2017
The Japanese Society of Internal Medicine